Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Hum Mol Genet ; 24(1): 118-27, 2015 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-25143393

RESUMEN

In humans, the elucidation of the genetics underlying multifactorial diseases such as pre-eclampsia remains complex. Given the current day availability of genome-wide linkage- and expression data pools, we applied pathway-guided genome-wide meta-analysis guided by the premise that the functional network underlying these multifactorial syndromes is under selective genetic pressure. This approach drastically reduced the genomic region of interest, i.e. 2p13 linked with pre-eclampsia in Icelandic families, from 8 679 641 bp (region with linkage) to 45 264 bp (coding exons of prioritized genes) (0.83%). Mutation screening of the candidate genes (n = 13) rapidly reduced the minimal critical region and showed the INO80B gene, encoding a novel winged helix domain (pfam14465) and part of the chromatin-remodeling complex, to be linked to pre-eclampsia. The functional defect in placental cells involved a susceptibility allele-dependent loss-of-gene silencing due to increased INO80B RNA stability as a consequence of differential binding of miR-1324 to the susceptibility allele of rs34174194. This risk allele is located at position 1 in an absolutely conserved 7-mer (UUGUCUG) in the 3-UTR of INO80B immediately downstream of a variant Pumillio Recognition Element (UGUANAAG). These data support that pre-eclampsia genes affect a conserved fundamental mechanism that evolved as a consequence of hemochorial placentation. Functionally, this involves founder-dependent, placentally expressed paralogous genes that regulate an essential trophoblast differentiation pathway but act at different entry points.


Asunto(s)
Proteínas de Ciclo Celular/genética , Estudios de Asociación Genética/métodos , MicroARNs/genética , Proteínas Nucleares/genética , Preeclampsia/genética , Análisis Mutacional de ADN/métodos , Femenino , Predisposición Genética a la Enfermedad , Humanos , Islandia , Péptidos y Proteínas de Señalización Intracelular/genética , Placenta/metabolismo , Polimorfismo de Nucleótido Simple , Embarazo
2.
Sci Rep ; 6: 32129, 2016 08 24.
Artículo en Inglés | MEDLINE | ID: mdl-27555360

RESUMEN

The familial forms of early onset pre-eclampsia and related syndromes (HELLP) present with hypertension and proteinuria in the mother and growth restriction of the fetus. Genetically, these clinically similar entities are caused by different founder-dependent, placentally-expressed paralogous genes. All susceptibility genes (STOX1, lincHELLP, INO80B) identified so far are master control genes that regulate an essential trophoblast differentiation pathway, but act at different entry points. Many genes remain to be identified. Here we demonstrate that a long non-coding RNA (lncRNA) within intron 3 of the STOX2 gene on 4q35.1 acts as a permissive cis-acting regulator of alternative splicing of STOX2. When this lncRNA is mutated or absent, an alternative exon (3B) of STOX2 is included. This introduces a stop codon resulting in the deletion of a highly conserved domain of 64 amino acids in the C-terminal of the STOX2 protein. A mutation present within a regulatory region within intron 1 of STOX2 has the same effect after blocking with CRISPR technology: transcripts with exon 3B are upregulated. This proces appears related to transcriptional control by a chromatin-splicing adaptor complex as described for FGFR2. For STOX2, CHD5, coding for a chromodomain helicase DNA binding protein, qualifies as the chromatin modifier in this process.


Asunto(s)
Proteínas Portadoras/genética , Cromosomas Humanos Par 4 , Preeclampsia/genética , ARN no Traducido/genética , Empalme Alternativo , Sistemas CRISPR-Cas , Femenino , Finlandia , Predisposición Genética a la Enfermedad , Humanos , Intrones , Masculino , Mutación , Linaje , Placenta/citología , Placenta/fisiología , Polimorfismo de Nucleótido Simple , Embarazo , Trofoblastos/patología
3.
J Clin Invest ; 122(11): 4003-11, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23093777

RESUMEN

The HELLP syndrome is a pregnancy-associated disease inducing hemolysis, elevated liver enzymes, and low platelets in the mother. Although the HELLP symptoms occur in the third trimester in the mother, the origin of the disease can be found in the first trimester fetal placenta. A locus for the HELLP syndrome is present on chromosome 12q23 near PAH. Here, by multipoint nonparametric linkage, pedigree structure allele sharing, and haplotype association analysis of affected sisters and cousins, we demonstrate that the HELLP locus is in an intergenic region on 12q23.2 between PMCH and IGF1. We identified a novel long intergenic noncoding RNA (lincRNA) transcript of 205,012 bases with (peri)nuclear expression in the extravillous trophoblast using strand-specific RT-PCR complemented with RACE and FISH. siRNA-mediated knockdown followed by RNA-sequencing, revealed that the HELLP lincRNA activated a large set of genes that are involved in the cell cycle. Furthermore, blocking potential mutation sites identified in HELLP families decreased the invasion capacity of extravillous trophoblasts. This is the first large noncoding gene to be linked to a Mendelian disorder with autosomal-recessive inheritance.


Asunto(s)
Ciclo Celular/genética , Cromosomas Humanos Par 12 , Enfermedades Genéticas Congénitas , Sitios Genéticos , Síndrome HELLP , ARN Largo no Codificante , Trofoblastos/metabolismo , Cromosomas Humanos Par 12/genética , Cromosomas Humanos Par 12/metabolismo , Familia , Femenino , Enfermedades Genéticas Congénitas/genética , Enfermedades Genéticas Congénitas/metabolismo , Enfermedades Genéticas Congénitas/patología , Estudio de Asociación del Genoma Completo , Síndrome HELLP/genética , Síndrome HELLP/metabolismo , Síndrome HELLP/patología , Humanos , Masculino , Linaje , Embarazo , Primer Trimestre del Embarazo/genética , Primer Trimestre del Embarazo/metabolismo , Tercer Trimestre del Embarazo/genética , Tercer Trimestre del Embarazo/metabolismo , ARN Largo no Codificante/genética , ARN Largo no Codificante/metabolismo , Trofoblastos/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA